Myovant Sciences's Enterprise Value for the quarter that ended in Mar. 2022 was $1,197.2 Mil.
Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-187.0 Mil. Myovant Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2022 was -15.63%.
The historical rank and industry rank for Myovant Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MYOV'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24.84 Med: -15.15 Max: -10.11
Current: -15.6
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Myovant Sciences was -10.11%. The lowest was -24.84%. And the median was -15.15%.
MYOV's Earnings Yield (Joel Greenblatt) % is ranked worse than 56.17% of 1556
companies
in the Biotechnology industry
Industry Median: -10.11
vs MYOV: -15.60
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Myovant Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Myovant Sciences Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Myovant Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Earnings Yield (Joel Greenblatt) %
-11.44
-15.90
-38.02
-15.70
-15.63
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Earnings Yield (Joel Greenblatt) %
-15.70
-14.35
-12.21
-16.34
-15.63
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Earnings Yield (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Myovant Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2022 is calculated as
Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187.0 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Myovant Sciences Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.51(3.7%) Volume: 712,123 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
